Amgen announced strong third-quarter 2025 financial results, with total revenues increasing 12% to $9.6 billion, driven by a 14% surge in product sales volume. While GAAP EPS rose 14% to $5.93, non-GAAP EPS saw a modest 1% increase due to a 31% jump in R&D spending to advance its late-stage pipeline, including the obesity drug MariTide.
AbbVie announced third-quarter 2025 net revenues of $15.776 billion, a 9.1% increase, fueled by strong growth from its immunology drugs Skyrizi and Rinvoq. GAAP diluted EPS was $0.10, impacted by IPR&D expenses, while adjusted diluted EPS was $1.86. Following the strong quarter, AbbVie raised its full-year 2025 adjusted diluted EPS guidance to $10.61 – $10.65.
Gilead Sciences (GILD) reported strong Q3 2025 financial results, with total revenues of $7.8 billion and non-GAAP diluted EPS jumping 22% to $2.47. The performance was driven by a 4% rise in its core business (excluding Veklury), led by its HIV franchise and $3.7 billion in Biktarvy sales. Despite a decline in Veklury and Cell Therapy revenue, the company raised its full-year 2025 diluted EPS guidance.
Eli Lilly reported blockbuster Q3 2025 earnings, with revenue hitting $17.6 billion on 54% year-over-year growth. The financial success was overwhelmingly driven by its incretin portfolio, particularly the high-demand GLP-1 drugs Mounjaro and Zepbound, which saw their sales soar. Following the strong performance and R&D momentum including positive Phase 3 data for the oral obesity drug orforglipron Lilly significantly raised its full-year 2025 revenue and EPS guidance.
For the third quarter that concluded on September 30, 2025, IQVIA Holdings Inc. (NYSE: IQV) posted solid financial results. The company’s profit and revenue were [Read More…]
Leading pharmaceutical companies including Roche, Eli Lilly, AbbVie, and Gilead/Kite are set to present significant new data from their oncology pipelines at the ESMO Congress 2025 in Berlin (Oct 17-21). Presentations will highlight advancements in targeted therapies, ADCs, and cell therapy for multiple cancer types, focusing on key drugs like Tecentriq, Verzenio, and Trodelvy.
Johnson & Johnson announced robust second-quarter 2025 financial results, surpassing analyst expectations and raising its full-year guidance. The healthcare giant reported a significant 5.8% increase in sales to $23.7 billion, driven by strong performances in its Innovative Medicine and MedTech segments.
